众生药业
(002317)
| 流通市值：198.38亿 | | | 总市值：219.54亿 |
| 流通股本：7.68亿 | | | 总股本：8.50亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,000,420,115.22 | 624,239,320.67 | 2,522,737,619.7 | 1,888,753,875.6 |
| 营业收入 | 1,000,420,115.22 | 624,239,320.67 | 2,522,737,619.7 | 1,888,753,875.6 |
| 二、营业总成本 | 888,603,999.58 | 514,225,795.98 | 2,225,746,035.9 | 1,625,683,280.09 |
| 营业成本 | 436,930,790.14 | 266,632,302.08 | 1,107,007,576.85 | 816,027,661.18 |
| 税金及附加 | 8,782,465.83 | 6,086,212.43 | 20,257,110.33 | 14,251,933.37 |
| 销售费用 | 348,775,162.65 | 197,500,169.04 | 869,866,759.61 | 641,202,996.53 |
| 管理费用 | 66,753,701.68 | 30,343,563.04 | 142,855,933.54 | 99,086,287 |
| 研发费用 | 29,371,829.26 | 14,635,225.78 | 91,028,059.82 | 59,919,853.27 |
| 财务费用 | -2,009,949.98 | -971,676.39 | -5,269,404.25 | -4,805,451.26 |
| 其中:利息费用 | 751,976.94 | 378,303.73 | 4,996,927.17 | 3,530,303.79 |
| 其中:利息收入 | 2,318,052.46 | 969,703.22 | 8,861,662.58 | 7,387,135.77 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -23,943,057.03 | -13,168,866.19 | -19,489,239.27 | -7,024,206.21 |
| 加:投资收益 | 7,983,362.09 | 3,457,821.09 | 16,577,557.9 | 12,824,619.97 |
| 资产处置收益 | 6,187,070.22 | 3,924,528.3 | 6,049,345.32 | 5,198,596.9 |
| 资产减值损失(新) | -1,387,938.02 | -26,435.49 | -22,572,227.89 | -2,094,559.03 |
| 信用减值损失(新) | 4,394,013.81 | 42,490.6 | -8,145,202.19 | -6,276,546.77 |
| 其他收益 | 14,263,962.65 | 7,947,099.14 | 28,887,676.25 | 23,040,330.31 |
| 四、营业利润 | 119,313,529.36 | 112,190,162.14 | 298,299,493.92 | 288,738,830.68 |
| 加:营业外收入 | 5,618,198.32 | 5,555,765.06 | 1,240,188.83 | 159,271.57 |
| 减:营业外支出 | 1,333,276.72 | 53,590.83 | 2,953,849.23 | 1,561,786.21 |
| 五、利润总额 | 123,598,450.96 | 117,692,336.37 | 296,585,833.52 | 287,336,316.04 |
| 减:所得税费用 | 16,851,480.66 | 19,667,105.03 | 29,881,264.63 | 41,838,658.7 |
| 六、净利润 | 106,746,970.3 | 98,025,231.34 | 266,704,568.89 | 245,497,657.34 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 106,746,970.3 | 98,025,231.34 | 266,704,568.89 | 245,497,657.34 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 111,423,979.07 | 99,822,991.5 | 275,754,918.87 | 250,578,030.92 |
| 少数股东损益 | -4,677,008.77 | -1,797,760.16 | -9,050,349.98 | -5,080,373.58 |
| 扣除非经常损益后的净利润 | 120,783,851.89 | 102,671,532.63 | 281,056,460.86 | 245,594,335.52 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.13 | 0.12 | 0.33 | 0.3 |
| (二)稀释每股收益 | 0.13 | 0.12 | 0.33 | 0.3 |
| 八、其他综合收益 | -810,552.41 | -465,901.91 | -5,349,740.05 | -6,583,447.99 |
| 归属于母公司股东的其他综合收益 | -810,552.41 | -465,901.91 | -5,349,740.05 | -6,583,447.99 |
| 九、综合收益总额 | 105,936,417.89 | 97,559,329.43 | 261,354,828.84 | 238,914,209.35 |
| 归属于母公司股东的综合收益总额 | 110,613,426.66 | 99,357,089.59 | 270,405,178.82 | 243,994,582.93 |
| 归属于少数股东的综合收益总额 | -4,677,008.77 | -1,797,760.16 | -9,050,349.98 | -5,080,373.58 |
| 公告日期 | 2026-08-25 | 2026-04-29 | 2026-04-29 | 2025-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |